Nobody dares to stop clinical research, not even COVID-19
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
PAMELA Phase II
HER2-low breast cancer: clinical and pathological overview
Improving global access to anticancer drugs
Eribulin plus Balixafortide Phase 1
Pernas, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Pérez-García J, Wach A, Barker D, Fung S, Romagnoli B, Cortés J. The CXCR4 antagonist, balixafortide, plus eribulin in HER2-negative metastatic breast […]